Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cara Therapeutics (CARA) PT Raised to $24 at H.C. Wainwright; 'Premier Partnership Incrementally De-Risks IV Korsuva'
May 23, 2018 12:44 PM EDTH.C. Wainwright raised its price target on Cara Therapeutics (NASDAQ: CARA) to $24.00 (from $22.00) while maintaining a Neutral rating.
... MoreCara Therapeutics (CARA) PT Raised to $20 at Stifel Following Vifor-Fresenius JV
May 23, 2018 11:01 AM EDTStifel raised its price target on Cara Therapeutics (NASDAQ: CARA) to $20.00 (from $17.00) while maintaining a Buy rating after the company announced a licensing arrangement with Vifor Fresenius Medical Care Renal Pharma (VFMCRP)a joint venture between Vifor Pharma (market leading provider of renal drugs) and... More
Cara Therapeutics (CARA) Bullish View Reiterated at Laidlaw Following Licence Agreement with Vifor Fresenius Medical
May 23, 2018 11:00 AM EDTLaidlaw analyst Francois Brisebois reiterated a Buy rating and $26 price target on Cara Therapeutics (NASDAQ: CARA) after the company announced that they have licensed worldwide rights (except US, Japan and South Korea) to commercialize Korsuva injection for the treatment of CKD-aP in dialysis patients to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).
Brisebois commented, "We are encouraged by the financial implications of the licensing as CARA will receive an upfront... More
Needham & Company Maintains Bullish View on Cara Therapeutics (CARA) Following IV CR845 License Agreement
May 23, 2018 10:26 AM EDTNeedham & Company analyst Alan Carr reiterated a Buy rating and $23 price target on Cara Therapeutics (NASDAQ: CARA) after the company announced this morning a license and co-promotion agreement with Vifor Fresenius Medical Care Renal Pharma (VF).
Carr commented, "The agreement relates... More
